SCHEMBL1037033

SCHEMBL1037033

Cc1noc(NC(=O)N2CCC(=Cc3cccc(OCC4CCC(F)(F)CC4)c3)CC2)c1C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.42
CYP2D6 P10635 4/20 0.42
FAAH O00519 7/20 0.39
GABRA1 P14867 1/20 0.39
ADRA2C P18825 1/20 0.39
CNR1 P21554 1/20 0.39
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
CNR2 P34972 1/20 0.39
HTR2B P41595 1/20 0.39
TMEM97 Q5BJF2 1/20 0.39
SIGMAR1 Q99720 1/20 0.39
OGA O60502 2/20 0.38
CCR5 P51681 1/20 0.33
PTPN1 P18031 1/20 0.33
MEN1 O00255 1/20 0.33
MAPK1 P28482 1/20 0.33
KMT2A Q03164 1/20 0.33
HSD17B10 Q99714 1/20 0.33
ENPP2 Q13822 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1036429 0.91 CYP3A4 (0.42) CYP3A4CYP2D6FAAHGABRA1ADRA2C
SCHEMBL6518264 0.89 CYP3A4 (0.33) CYP3A4CYP2D6FAAHGABRA1ADRA2C
SCHEMBL6518270 0.89 CYP3A4 (0.33) CYP3A4CYP2D6FAAHGABRA1ADRA2C
SCHEMBL1037994 0.88 CYP3A4 (0.42) CYP3A4CYP2D6FAAHGABRA1ADRA2C
SCHEMBL1037462 0.88 CYP3A4 (0.42) CYP3A4CYP2D6FAAHGABRA1ADRA2C
SCHEMBL1033156 0.86 CYP3A4 (0.40) CYP3A4CYP2D6FAAHGABRA1ADRA2C
SCHEMBL1036041 0.85 CYP3A4 (0.44) CYP3A4CYP2D6FAAHGABRA1ADRA2C
SCHEMBL1033477 0.85 CYP3A4 (0.43) CYP3A4CYP2D6FAAHGABRA1ADRA2C
SCHEMBL1038006 0.84 SMN1; SMN2 (0.42) CYP3A4CYP2D6FAAHGABRA1ADRA2C
SCHEMBL1035770 0.83 CYP3A4 (0.61) CYP3A4CYP2D6FAAHGABRA1ADRA2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110053982-A1 ETHER BENZYLIDENE PIPERIDINE 5-MEMBERED ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS PFIZER INC. (US) 2011-03-03 US claimed
US-20110053982-A1 ETHER BENZYLIDENE PIPERIDINE 5-MEMBERED ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS PFIZER INC. (US) 2011-03-03 US disclosed
EP-2276738-A1 ETHER BENZYLIDENE PIPERIDINE 5-MEMBERED ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS Pfizer Inc. (US) 2011-01-26 EP disclosed
WO-2009127943-A1 ETHER BENZYLIDENE PIPERIDINE 5-MEMBERED ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS PFIZER INC. (US) 2009-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053982-A1 ETHER BENZYLIDENE PIPERIDINE 5-MEMBERED ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS FAAH, FAAH2, CNR2 CYP3A4 524/4885CYP2D6 316/4885FAAH 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.